This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: The evidence from prospective observational research for a protective effect of antihypertensive drug use on the risk of dementia is far from uniform. Duration of follow-up was limited and relied mainly on baseline drug exposure data without information on duration of use. We investigated the association between the duration of antihypertensive use and risk of dementia.
Methods: We followed 6,249 participants (mean 68.4 years, 60% women) of a prospective, population-based cohort from baseline (1990–1993) until 2005 for incident dementia. Continuous data on filled prescriptions came from pharmacy records. Total cumulative duration of antihypertensive use was expressed in years. We subtracted a latent 4-year period before the date of dementia diagnosis in the quantification of exposure duration to avoid potential bias in antihypertensive prescription due to prodromal changes in blood pressure or cognition. With Cox regression models, we calculated crude and adjusted hazard ratios (HRs) of all dementia and Alzheimer disease (AD) with antihypertensive use vs never used.
Results: Compared to never used, antihypertensive use was associated with a reduced risk of all dementia (adjusted HR per year of use 0.95; 95% confidence interval [CI] 0.91–0.99). We observed an 8% (95% CI −15% to −1%) risk reduction per year of use for persons ≤75 years, whereas for persons >75 years this was 4% (95% CI −11% to 4%). Equivalent estimates were observed for AD. No apparent differences were observed among different types of antihypertensive drugs.
Conclusions: Antihypertensive drug use was associated with 8% risk reduction of dementia per year of use for persons ≤75 years.
Glossary
- ACE=
- angiotensin-converting enzyme;
- AD=
- Alzheimer disease;
- AT2=
- angiotensin-2;
- ATC=
- Anatomic Therapeutic Chemical;
- BMI=
- body mass index;
- BP=
- blood pressure;
- CCB=
- calcium channel blocker;
- CHD=
- coronary heart disease;
- CI=
- confidence interval;
- DBP=
- diastolic blood pressure;
- DHP=
- dihydropyridine;
- DM=
- diabetes mellitus;
- DSM=
- Diagnostic and Statistical Manual of Mental Disorders;
- GMS=
- Geriatric Mental State schedule;
- HR=
- hazard ratio;
- MI=
- myocardial infarction;
- MMSE=
- Mini-Mental State Examination;
- NINCDS-ADRDA=
- National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association;
- NINDS-AIREN=
- National Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche en l'Enseignement en Neurosciences;
- OR=
- odds ratio;
- RR=
- relative risk;
- SBP=
- systolic blood pressure.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg